

To the editor:

Cladribine added to daunorubicin-cytarabine induction prolongs survival of *FLT3*-ITD⁺ normal karyotype AML patients

Marta Libura,¹ Sebastian Giebel,² Beata Piatkowska-Jakubas,³ Marta Pawelczyk,¹ Izabella Florek,³ Karolina Matiakowska,⁴ Bozena Jazwiec,⁵ Katarzyna Borg,⁶ Iwona Solarska,⁶ Magdalena Zawada,³ Sylwia Czekalska,³ Jolanta Libura,¹ Malgorzata Jakobczyk,³ Karolina Karabin,¹ Monika Paluszewska,¹ Malgorzata Calbecka,⁷ Justyna Gajkowska-Kulik,⁷ Grazyna Gadomska,⁸ Marek Kielbinski,⁵ Anna Ejduk,⁶ Dariusz Kata,⁹ Sebastian Grosicki,¹⁰ Agnieszka Wierzbowska,¹¹ Slawomira Kyrzcz-Krzemien,⁹ Krzysztof Warzocha,⁶ Kazimierz Kuliczkowski,⁵ Aleksander Skotnicki,³ Jerzy Holowiecki,² Wieslaw Wiktor Jedrzejczak,¹ and Olga Haus^{4,5}

¹Medical University of Warsaw, Warsaw, Poland; ²Maria Sklodowska-Curie Institute of Oncology, Gliwice, Poland; ³Faculty of Medicine, Jagiellonian University, Cracow, Poland; ⁴Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland; ⁵Medical University of Wrocław, Wrocław, Poland; ⁶Institute of Hematology and Transfusion Medicine, Warsaw, Poland; ⁷Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland; ⁸Dr Biziel University Hospital, Bydgoszcz, Poland; ⁹Medical University of Silesia, Katowice, Poland; ¹⁰Municipal Specialist Hospital in Chorzow, Chorzow, Poland; and ¹¹Medical University of Lodz, Lodz, Poland

Internal tandem duplication in the *FLT3* gene (*FLT3*-ITD) has been recognized as a marker conferring poor outcome in patients with normal karyotype acute myeloid leukemia (NK-AML).¹ Because of the inferior outcome of *FLT3*-ITD⁺ NK-AML patients when treated with standard daunorubicin-cytarabine (AraC) 3+7 induction (DA), this group prompts the use of investigational therapy. So far, clinical experiences of targeting the *FLT3* receptor signaling failed to demonstrate efficacy of such an approach.²

Cladribine is a purine analog that acts by increasing cellular uptake of AraC in leukemic blasts as well as by directly inhibiting DNA synthesis.³ As demonstrated in 2 subsequent studies by the Polish Adult Leukemia Group (PALG), the addition of cladribine to DA (DAC) was associated with an increased complete remission (CR) rate and prolonged overall survival (OS) in the general AML population, with the most prominent effect in patients with unfavorable cytogenetics.^{4,5} Because the previous studies did not include molecular results, we have performed a retrospective analysis of *FLT3*-ITD and nucleophosmin 1 (*NPM1*) mutations in the DNA of AML patients treated either in randomized trials or according to the same protocols outside prospective studies. The aim of this study was to compare efficacy of DAC and DA regimens in different subgroups according to the presence or absence of *FLT3*-ITD, with OS as the primary end point of the study.

A total of 227 samples from newly diagnosed NK-AML patients were analyzed retrospectively for *FLT3*-ITD and *NPM1* mutations.^{6,7} The main characteristics of patients treated using DA vs DAC are summarized in Table 1 (part A). Patients were treated in 9 PALG centers in the years 1999 through 2014. Details of the treatment, response end points, and statistical methods are provided in the supplemental Material, available on the *Blood* Web site. All samples were obtained after written informed consent was obtained in accordance with the Declaration of Helsinki. The study was approved by the local bioethical committees.

In the entire group of patients, CR was achieved in 77.1% (175 patients), which was consistent with the observations of others.^{1,8-10} In the DA-treated group, the CR rate was 73.4% (91/124), whereas in DAC-treated patients, the CR rate was 81.6% (84/103), with a trend toward a statistically significant difference between both arms ($P = .14$). Interestingly, among the *FLT3*-ITD⁺ patients, the CR rate after DAC was 86% (19/22), whereas it was 61% (20/33) after the DA regimen, with the statistically significant difference between

both induction groups ($P = .04$; see Table 1, part B). We could not demonstrate the same difference for *FLT3*-ITD⁻ patients. In multivariate analysis adjusted for age and *NPM1* mutations, there was a tendency toward reduced risk of induction failure in the group of *FLT3*-ITD⁺ patients treated in the DAC arm (odds ratio [OR] = 0.25; 95% confidence interval [CI], 0.06-1.14; $P = .07$; see Table 1, part C).

With a median follow-up for survivors of 3.69 years, the 4-year probability of OS for the whole group was 34% (standard error ± 3), and the median survival was 18 months. For the whole study group, OS was improved in the DAC (41%) when compared with the DA arm (30.4%), but only a trend toward statistical significance was observed ($P = .15$). However, when the group was stratified according to *FLT3*-ITD, an OS advantage could be demonstrated for *FLT3*-ITD⁺ patients treated with DAC (37%) when compared with the DA arm (14%; $P = .05$), with the most prominent OS improvement after censoring the observation at the time of allogeneic hematopoietic stem cell transplantation (alloHSCT; $P = .007$; see Table 1, part B and Figure 1). Interestingly, cladribine seems to present OS advantage for patients with high as well as low *FLT3*-mutant-to-wild-type allelic ratio, although the most prominent effect was observed in the poor-risk patients with high mutant-to-wild-type ratio (60% vs 18% for DAC- and DA-treated patients, respectively; $P = .04$; see supplemental Figure 1). In regard to co-occurring *NPM1*⁺ mutation, we observed statistically different OS between the DAC and DA arms in the *NPM1*⁺/*FLT3*-ITD⁺ population (38% vs 8%, respectively; $P = .026$). Cladribine seems to also be effective in poor-risk *NPM1*⁻ patients; however, the results need to be confirmed in a larger group of patients (supplemental Figure 2A-B). In multivariate analysis, DAC induction was independently associated with a reduced risk of mortality in *FLT3*-ITD⁺ patients and this effect was particularly prominent when observations were censored at the time of alloHSCT (hazard ratio [HR] = 0.36; 95% CI, 0.167-0.775; $P = .009$).

In the entire group of patients, independently from the type of induction, we did not see a negative impact of *FLT3*-ITD on the CR rate (70.1% vs 79% for *FLT3*-ITD⁺ vs *FLT3*-ITD⁻ AML; NS). Different studies showed the ambiguous impact of *FLT3*-ITD on the CR rate: in some groups, *FLT3*-ITD⁺ patients were associated with a decreased CR,⁸ whereas others reported a lack of significant difference between 2 genetic subgroups.^{9,10} Thus,

Table 1. Biological, hematologic, and clinical data of NK-AML patients

A. Demographic data of the patients				
Characteristics	DAC (n = 103)	DA (n = 124)	P	Total no. (N = 227)
Median age (y)	49	50	.49*	50 y‡
<i>NPM1</i>(^{+/+})/<i>FLT3</i>-ITD(^{+/+})§				
1st N ⁻ /F ⁻	54 (54%)	60 (49%)	.54†	114
2nd N ⁺ /F ⁻	25 (25%)	29 (24%)	.88†	54
3rd N ⁻ /F ⁺	3 (3%)	11 (9%)	.09†	14
4th N ⁺ /F ⁺	19 (19%)	22 (18%)	.89†	41
Median initial WBC (×10 ⁶)	33	21.2	.88*	28‡
Sex	55 F, 48 M	72 F, 52 M	.48†	127 F, 100 M
De novo AML	101 (98%)	113 (91%)	.03†	214
Sec MDS AML	2 (2%)	10 (8%)	.07†	12
Sec Th AML	0	1 (0.8%)	.9†	1
FAB				
M0	8 (8%)	8 (6%)	.8†	16
M1	28 (27%)	35 (29%)	.86†	63
M2	25 (24%)	34 (28%)	.59†	59
M4	36 (35%)	27 (21%)	.03†	63
M5	5 (5%)	20 (16%)	.07†	25
M6	1 (1%)	0 (0%)	.45†	1
B. Results of univariate analysis for all patients (N = 227)				
End point and variables	DAC (n = 103)	DA (n = 124)	P	
CR rate, number of patients (%)				
<i>FLT3</i>-ITD				
NEG	65/81 (80%)	71/91 (78%)	.72†	
POS	19/22 (86%)	20/33 (61%)	.04†	
OS, number of patients, 4-y rate, % (SD)				
<i>FLT3</i>-ITD				
NEG	n = 81; 43% (6)	n = 91; 36% (5)	.6¶	
POS	n = 22; 37% (11)	n = 33; 14% (7)	.051¶	
OS censored at allograft, number of patients, 4-y rate, % (SD)				
<i>FLT3</i>-ITD				
NEG	n = 81; 37% (8)	n = 91; 28% (6)	.61¶	
POS	n = 22; 37% (13)	n = 33; 5% (5)	.007¶	
C. Multivariate analysis restricted to <i>FLT3</i>-ITD⁺ patients (N = 55)				
End point and variables	Hazard ratio (95% CI)		P	
CR				
DAC vs DA	0.25 (0.06-1.14)		.07	
Age (continuous)	1.08 (1-1.16)		.04	
<i>NPM1</i> ⁺	0.61 (0.14-2.62)		.5	
OS				
DAC vs DA	0.507 (0.257-1.001)		.05	
<i>NPM1</i> ⁺	1.084 (0.52-2.262)		.83	
Age (continuous)	1.018 (0.984-1.053)		.3	
OS censored at allograft				
DAC vs DA	0.36 (0.167-0.775)		.009	
<i>NPM1</i> ⁺	1.074 (0.468-2.464)		.87	
Age (continuous)	1.022 (0.988-1.058)		.21	

CRR, complete remission rate; FAB, French American British classification; MDS, myelodysplastic syndrome; *NPM1*⁺, mutations in *nucleophosmin* gene; SD, standard deviation; sec MDS AML, secondary to MDS AML; sec Th AML, secondary to chemotherapy AML; WBC, white cells blood count.

A, Patients' characteristics; B-C, early and long-term outcome by treatment arms in subgroups according to *FLT3*-ITD status.

*Computed by the Mann-Whitney *U* test.

†Computed by the Fisher exact test or χ^2 .

‡Median value for total patient group.

§For 4 *FLT3*-ITD⁻ patients, *NPM1* status was not established.

¶Computed by log-rank test.

||Computed by Cox regression analysis.

it is possible that this effect might depend on the type of induction because it was already documented for *DNMT3A* mutation.¹¹ In our group, the *FLT3*-ITD⁺ patients treated with the standard DA protocol presented a lower CR rate when compared with *FLT3*-ITD⁻ NK-AML patients (64.5% vs 82.5%, respectively; *P* = .038). In contrast, in the DAC arm the CR rate was not statistically different between *FLT3*-ITD⁺ and *FLT3*-ITD⁻ subgroups of patients (86% vs 80%, respectively; *P* = .3). Thus, we might conclude that the addition of cladribine abolishes the negative effect of *FLT3*-ITD on the CR of NK-AML patients.

Recent data suggest that the negative effect of *FLT3*-ITD could be potentially overcome by escalation of the drug doses used in induction. Indeed, Boissel et al⁹ documented that reinforced double induction regimens could overcome the negative prognostic impact of *FLT3*-ITD in patients enrolled prospectively in the ALFA-9000 trial. The study by Luskin et al¹² showed that escalated doses of daunorubicin might improve the outcome of *FLT3*-ITD⁺ AMLs, suggesting again that successful treatment of AML depends on the optimal drug doses used at the very beginning of the therapy.¹⁰⁻¹³

However, further drug dose intensification during induction might be a false approach in *FLT3*-ITD⁺ patients. This group presented particularly frequent variants of single-nucleotide polymorphisms in genes encoding the AraC-metabolizing enzymes, which correlated with higher toxicity of high-dose Ara-C and thus shorter survival of *FLT3*-ITD⁺ patients.^{14,15} In our setting, the standard dose of AraC accompanied by cladribine allowed *FLT3*-ITD⁺ patients to achieve CR rates comparable with the *FLT3*-ITD⁻ subgroup. Thus, our data suggest that cladribine presents an effective and relatively safe solution for *FLT3*-ITD⁺ AMLs.

Among current postremission therapy protocols, alloHSCt remains until now the standard procedure, increasing long-term survival of *FLT3*-ITD⁺ patients.¹⁰ Interestingly, the effect of cladribine on OS was the strongest when observations were censored at the time of alloHSCt. Moreover, we found that OS in the DA arm differed significantly between *FLT3*-ITD⁺ and *FLT3*-ITD⁻ patients in the group receiving chemotherapy alone as postremission therapy (7% vs 20%, respectively; *P* = .018). In contrast, in the DAC arm receiving chemotherapy alone, we could not document the same difference (33% vs 29% for *FLT3*-ITD⁺ vs *FLT3*-ITD⁻ patients, respectively; *P* = .57). Therefore, the addition of cladribine might be of particular importance when alloHSCt for various reasons cannot be done, because of advanced age of patient or lack of an HLA-matched donor that cannot be foreseen at the time of diagnosis. Thus,




Figure 1. Kaplan-Meier estimates for the probability of OS.

the addition of cladribine seems a reasonable option to be considered for all *FLT3*-ITD⁺ patients.

In recent years, targeted therapy has been proposed as the most promising treatment option for *FLT3*-ITD⁺ patients. Recent data, however, does not show convincing results regarding their clinical application.² In summary, our data demonstrate that cladribine could abolish the negative effect of *FLT3*-ITD on survival of NK-AML patients and thus might present an interesting and safe solution for *FLT3*-ITD⁺ AML patients.

The retrospective nature of our study, as well as the relatively small number of *FLT3*-ITD⁺ AML patients included in the analysis, is the most serious limitation of the obtained data. Our results, however, provide a rationale to carry out prospective studies on the role of cladribine in the treatment of different genetic subgroups of NK-AML patients.

The online version of this article contains a data supplement.

Acknowledgments: All DNA sequencing reactions were performed in the Sequencing and Oligonucleotide Synthesis Laboratory at IBB, Polish Academy of Sciences in Warsaw and partially sponsored by this Laboratory.

This study was supported by grant PBZ-KBN-120/P05/2004 funded by the Polish Ministry of Science and Education, coordinated by the International Institute of Molecular and Cell Biology in Warsaw; a scholarship from the Postgraduate School of Molecular Medicine at the Medical University of Warsaw (M.L., M. Pawelczyk, K. Karabin); Marie Curie International grant MOICT-2005-0514870 within 6th European Community Framework (J.L.); and Collegium Medicum in Bydgoszcz Nicolaus Copernicus University (no 181/2009).

Contribution: M.L., M. Pawelczyk, I.F., K.M., B.J., K.B., I.S., M.Z., S.C., J.L., M.J., and K. Karabin, performed the laboratory research; B.P.-J., M. Paluszewska, M.C., J.G.-K., G.G., M.K., A.E., D.K., S.G., A.W., S.K.-K., K.W., K. Kuliczowski, A.S., J.H., and W.W.J. performed patient management; M.L. and S.G. analyzed and interpreted the data; M.L. and S.G. wrote the manuscript; O.H. participated in construction of the manuscript and revised it critically; and all authors accepted the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Marta Libura, Hematology, Department of Hematology, Oncology and Internal Diseases, Medical University and University Hospital, 1A Banacha Str., 02-097 Warsaw, Poland; e-mail: marta.libura@gmail.com.

References

- Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008;358(18):1909-1918.
- Baker SD, Zimmerman EI, Wang YD, et al. Emergence of polyclonal *FLT3* tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in *FLT3*-ITD-positive acute myeloid leukemia. *Clin Cancer Res*. 2013;19(20):5758-5768.
- Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. *Leuk Lymphoma*. 2003;44(3):391-409.
- Holowiecki J, Grosicki S, Robak T, et al; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. *Leukemia*. 2004;18(5):989-997.
- Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. *J Clin Oncol*. 2012;30(20):2441-2448.
- Libura M, Asnafi V, Tu A, et al. *FLT3* and *MLL* intragenic abnormalities in AML reflect a common category of genotoxic stress. *Blood*. 2003;102(6):2198-2204.
- Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of *NPM1* mutations in 1485 adult patients with acute myeloid leukemia (AML). *Blood*. 2006;107(10):4011-4020.
- Kottaridis PD, Gale RE, Frew ME, et al. The presence of a *FLT3* internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood*. 2001;98(6):1752-1759.
- Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of *FLT3* internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. *Leukemia*. 2002;16(9):1699-1704.
- Fröhling S, Schlenk RF, Breitnick J, et al; AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating *FLT3* mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. *Blood*. 2002;100(13):4372-4380.
- Sehgal AR, Gimotty PA, Zhao J, et al. *DNMT3A* mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. *Clin Cancer Res*. 2015;21(7):1614-1620.
- Luskin MR, Lee J-W, Fernandez HF, et al. High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic risk groups including patients with unfavorable cytogenetic risk, and *FLT3*-ITD mutant AML: updated analyses from Eastern Cooperative Oncology Trial E1900 [abstract]. *Blood*. 2014;124(21). Abstract 373.
- Larson SM, Campbell NP, Huo D, et al. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). *Leuk Lymphoma*. 2012;53(3):445-450.
- Bhatla D, Gerbing RB, Alonzo TA, et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. *Br J Haematol*. 2009;144(3):388-394.
- Mahlknecht U, Dransfeld CL, Bulut N, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of *CDA* SNP C-451T as an independent prognostic parameter for survival. *Leukemia*. 2009;23(10):1929-1932.

DOI 10.1182/blood-2015-08-662130

© 2016 by The American Society of Hematology

To the editor:

Germline *RBBP6* mutations in familial myeloproliferative neoplasms

Ashot S. Harutyunyan,¹ Roberto Giambro, ¹ Christian Krendl, ¹ Alexey Stukalov, ¹ Thorsten Klampfl, ¹ Tiina Berg, ¹ Doris Chen, ¹ Jelena D. Milosevic Feenstra, ¹ Roland Jäger, ¹ Bettina Gisslinger, ² Heinz Gisslinger, ² Elisa Rumi, ³ Francesco Passamonti, ⁴ Daniela Pietra, ³ André C. Müller, ¹ Katja Parapatics, ¹ Florian P. Breitwieser, ¹ Richard Herrmann, ⁵ Jacques Colinge, ¹ Keiryn L. Bennett, ¹ Giulio Superti-Furga, ¹ Mario Cazzola, ³ Emma Hammond, ⁶ and Robert Kralovics^{1,2}

¹CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; ²Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria; ³Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; ⁴Department of Internal Medicine, Division of Hematology, University Hospital, Ospedale di Circolo, Varese, Italy; ⁵School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia; and ⁶Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Australia